National Cancer Institute Pediatric Preclinical Testing Program: Model Description for in Vitro Cytotoxicity Testing

Overview

Journal Pediatr Blood Cancer

Specialties Hematology
Oncology
Pediatrics

Date 2010 Oct 6

PMID 20922763

Citations 66

Authors

Min H Kang

Malcolm A Smith

Christopher L Morton

Nino Keshelava

Peter J Houghton

C Patrick Reynolds

Affiliations

Soon will be listed here.

Abstract

Background: The National Cancer Institute (NCI) has established the Pediatric Preclinical Testing Program (PPTP) for testing drugs against in vitro and in vivo childhood cancer models to aid in the prioritization of drugs considered for early phase pediatric clinical trials.

Procedures: In vitro cytotoxicity testing employs a semi-automated fluorescence-based digital imaging cytotoxicity assay (DIMSCAN) that has a 4-log dynamic range of detection. Curve fitting of the fractional survival data of the cell lines in response to various concentrations of the agents was used to calculate relative IC(50) , absolute IC(50) , and Y(min) values. The panel of 23 pediatric cancer cell lines included leukemia (n = 6), lymphoma (n = 2), rhabdomyosarcoma (n = 4), brain tumors (n = 3), Ewing family of tumors (EFT, n = 4), and neuroblastoma (n = 4). The doubling times obtained using DIMSCAN were incorporated into data analyses to estimate the relationship between input cell numbers and final cell number.

Results: We report in vitro activity data for three drugs (vincristine, melphalan, and etoposide) that are commonly used for pediatric cancer and for the mTOR inhibitor rapamycin, an agent that is currently under preclinical investigation for cancer. To date, the PPTP has completed in vitro testing of 39 investigational and approved agents for single drug activity and two investigational agents in combination with various "standard" chemotherapy drugs.

Conclusions: This robust in vitro cytotoxicity testing system for pediatric cancers will enable comparisons to response data for novel agents obtained from xenograft studies and from clinical trials.

Citing Articles

Design, Synthesis, and Antiproliferative Activity of Novel Indole/1,2,4-Triazole Hybrids as Tubulin Polymerization Inhibitors.

Mahmoud E, Abdelhamid D, Mohammed A, Almarhoon Z, Brase S, Youssif B Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006087 PMC: 11859928. DOI: 10.3390/ph18020275.

Coumarin-Based Aldo-Keto Reductase Family 1C (AKR1C) 2 and 3 Inhibitors.

Jonnalagadda S, Duan L, Dow L, Boligala G, Kosmacek E, McCoy K ChemMedChem. 2024; 19(21):e202400081.

PMID: 38976686 PMC: 11537819. DOI: 10.1002/cmdc.202400081.

Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trials.

Metts J, Aye J, Crane J, Oberoi S, Balis F, Bhatia S Cancer. 2024; 130(22):3785-3796.

PMID: 38941509 PMC: 11511643. DOI: 10.1002/cncr.35457.

The heterogeneous sensitivity of pediatric brain tumors to different oncolytic viruses is predicted by unique gene expression profiles.

Vazaios K, Stavrakaki E, Vogelezang L, Ju J, Waranecki P, Metselaar D Mol Ther Oncol. 2024; 32(2):200804.

PMID: 38694569 PMC: 11060958. DOI: 10.1016/j.omton.2024.200804.

DNA-PKcs as an upstream mediator of OCT4-induced MYC activation in small cell lung cancer.

Wei S, Yang I, Mohiuddin I, Kshirsagar G, Nguyen T, Trasti S Biochim Biophys Acta Gene Regul Mech. 2023; 1866(2):194939.

PMID: 37116859 PMC: 10243594. DOI: 10.1016/j.bbagrm.2023.194939.

References

McDermott U, Iafrate A, Gray N, Shioda T, Classon M, Maheswaran S . Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008; 68(9):3389-95. DOI: 10.1158/0008-5472.CAN-07-6186. View

Klein G, GIOVANELLA B, Westman A, STEHLIN J, Mumford D . An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology. 1975; 5(6):319-34. DOI: 10.1159/000149930. View

Stong R, Korsmeyer S, Parkin J, Arthur D, Kersey J . Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood. 1985; 65(1):21-31. View

Johnson J, Decker S, Zaharevitz D, Rubinstein L, Venditti J, SCHEPARTZ S . Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001; 84(10):1424-31. PMC: 2363645. DOI: 10.1054/bjoc.2001.1796. View

Keshelava N, Frgala T, Krejsa J, Kalous O, Reynolds C . DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods Mol Med. 2005; 110:139-53. DOI: 10.1385/1-59259-869-2:139. View

Rodriguez-Perales S, Martinez-Ramirez A, de Andres S, Valle L, Urioste M, Benitez J . Molecular cytogenetic characterization of rhabdomyosarcoma cell lines. Cancer Genet Cytogenet. 2003; 148(1):35-43. DOI: 10.1016/s0165-4608(03)00216-4. View

Maris J, Courtright J, Houghton P, Morton C, Kolb E, Lock R . Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008; 51(1):42-8. DOI: 10.1002/pbc.21535. View

Neale G, Su X, Morton C, Phelps D, Gorlick R, Lock R . Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res. 2008; 14(14):4572-83. PMC: 4209898. DOI: 10.1158/1078-0432.CCR-07-5090. View

Benjamin D, Magrath I, Maguire R, Janus C, Todd H, Parsons R . Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type. J Immunol. 1982; 129(3):1336-42. View

10.

Monga M, Sausville E . Developmental therapeutics program at the NCI: molecular target and drug discovery process. Leukemia. 2002; 16(4):520-6. DOI: 10.1038/sj.leu.2402464. View

11.

Gorlick R, Kolb E, Houghton P, Morton C, Phelps D, Schaiquevich P . Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009; 53(4):594-8. PMC: 2731000. DOI: 10.1002/pbc.21989. View

12.

FOLEY G, Lazarus H, Farber S, Uzman B, Boone B, McCarthy R . CONTINUOUS CULTURE OF HUMAN LYMPHOBLASTS FROM PERIPHERAL BLOOD OF A CHILD WITH ACUTE LEUKEMIA. Cancer. 1965; 18:522-9. DOI: 10.1002/1097-0142(196504)18:4<522::aid-cncr2820180418>3.0.co;2-j. View

13.

Kurmasheva R, Morton C, Houghton P . Developing new agents for the treatment of childhood cancer. Curr Opin Investig Drugs. 2005; 6(12):1215-27. View

14.

Petak I, Douglas L, Tillman D, Vernes R, HOUGHTON J . Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin Cancer Res. 2000; 6(10):4119-27. View

15.

Reaman G . Pediatric cancer research from past successes through collaboration to future transdisciplinary research. J Pediatr Oncol Nurs. 2004; 21(3):123-7. DOI: 10.1177/1043454204264406. View

16.

Whiteford C, Bilke S, Greer B, Chen Q, Braunschweig T, Cenacchi N . Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res. 2007; 67(1):32-40. DOI: 10.1158/0008-5472.CAN-06-0610. View

17.

Keshelava N, Zuo J, Chen P, Waidyaratne S, Luna M, Gomer C . Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res. 2001; 61(16):6185-93. View

18.

Keshelava N, Groshen S, Reynolds C . Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemother Pharmacol. 2000; 45(1):1-8. DOI: 10.1007/PL00006736. View

19.

Batra S, Reynolds C, Maurer B . Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res. 2004; 64(15):5415-24. DOI: 10.1158/0008-5472.CAN-04-0377. View

20.

Fischer P, Nacheva E, Mason D, Sherrington P, Hoyle C, Hayhoe F . A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood. 1988; 72(1):234-40. View